165 related articles for article (PubMed ID: 33926024)
1. In Vivo Imaging of Thyroid Cancer with
Galli F; Varani M; Lauri C; Campagna G; Balogh L; Weintraub BD; Szkudlinski MW; Bartolazzi A; Manni I; Piaggio G; Signore A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33926024
[TBL] [Abstract][Full Text] [Related]
2. (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.
Galli F; Manni I; Piaggio G; Balogh L; Weintraub BD; Szkudlinski MW; Fremont V; Dierckx RA; Signore A
Thyroid; 2014 Aug; 24(8):1297-308. PubMed ID: 24801227
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.
Reinfelder J; Maschauer S; Foss CA; Nimmagadda S; Fremont V; Wolf V; Weintraub BD; Pomper MG; Szkudlinski MW; Kuwert T; Prante O
Thyroid; 2011 Jul; 21(7):783-92. PubMed ID: 21568725
[TBL] [Abstract][Full Text] [Related]
4. Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer cells in vitro.
Kim CH; Yoo IeR; Chung YA; Park YH; Kim SH; Sohn HS; Chung SK
Ann Nucl Med; 2009 Feb; 23(2):131-6. PubMed ID: 19225935
[TBL] [Abstract][Full Text] [Related]
5. Use of
Wu D; Ylli D; Gomes Lima CJ; Lee W; Burman KD; Wartofsky L; Van Nostrand D
Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
[TBL] [Abstract][Full Text] [Related]
6. Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.
Gimblet GR; Whitt J; Houson HA; Lin D; Guenter R; Rao TC; Wang D; Ness J; Gonzalez ML; Murphy MS; Gillis A; Chen H; Copland JA; Kenderian SS; Lloyd RV; Szkudlinski MW; Lapi SE; Jaskula-Sztul R
Surgery; 2024 Jan; 175(1):199-206. PubMed ID: 37919223
[TBL] [Abstract][Full Text] [Related]
7. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
9. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
10. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Imaging of Tumor PD-L1 Expression Using [
Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
[TBL] [Abstract][Full Text] [Related]
12. The Value of
Okudan B; Seven B; Gülaldı NCM; Çapraz M; Açıkgöz Y
Curr Med Imaging; 2022; 18(4):404-408. PubMed ID: 34749623
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of
Zheng J; Miao W; Huang C; Lin H
Ann Nucl Med; 2017 Jul; 31(6):486-494. PubMed ID: 28474165
[TBL] [Abstract][Full Text] [Related]
16. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
17. Role of [
Xu Q; Liu R; Wang J; Huang Y; Li S; Zhang L; Wang F
Nucl Med Biol; 2020; 88-89():34-43. PubMed ID: 32688289
[TBL] [Abstract][Full Text] [Related]
18. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
